THE latest data pointing to a surge in malaria cases should trigger a serious alarm.
As of mid-April 2026, the country had recorded more than 65 000 malaria cases and 174 deaths — nearly double the figures reported during the same period in 2025.
The spike marks a dramatic setback compared to 2024, when Zimbabwe recorded approximately 17 000 cases and 34 deaths between January and April, before global aid cuts disrupted key health programmes.
These figures tell the story of a country that had grown comfortable with international partners playing a central role in malaria control.
For years, Zimbabwe was hailed as a success story in the fight against malaria. Cases were falling dramatically and some areas were even declared malaria-free. But the sudden rise in infections following aid cuts exposes a hard truth: progress built largely on donor funding can collapse just as quickly as the funding disappears.
The premature closure of malaria programmes following reductions in international support has left critical gaps in mosquito net distribution, vector control and disease surveillance. These are the very pillars that sustained Zimbabwe’s progress. Once they weaken, malaria inevitably resurfaces.
Keep Reading
- Malaria fight disrupted by COVID pandemic: WHO
- Malaria fight disrupted by COVID pandemic: WHO
- Co-operate to curb malaria, Mash West farmers urged
- Vaccines could be a game-changer in the fight against malaria in Africa
This should not come as a surprise. Public health programmes — particularly those aimed at eliminating diseases such as malaria — cannot operate as temporary projects dependent on the shifting priorities of global donors. They require consistent and predictable funding.
Expecting international organisations such as Save the Children or the World Health Organisation to carry the burden indefinitely is unrealistic. Donor funding is shaped by global crises, geopolitical interests and competing priorities. When the world’s attention shifts, countries that depend heavily on aid are left dangerously exposed.
The situation has been further complicated by the inward-looking policies associated with Donald Trump’s “Make America Great Again” agenda, which emphasises domestic priorities over international assistance.
The United States has provided more than US$180 million since 2011 to support Zimbabwe’s malaria control programmes. While this assistance has played a significant role in reducing infections and saving lives, the recent surge in cases highlights the risks of relying heavily on external funding.
This reality should compel Zimbabwe to rethink its strategy. The fight against malaria must increasingly be financed at home, with co-operating partners complementing — not replacing — domestic efforts.
Malaria prevention must become a central component of the national health budget, ensuring sustained funding for programmes such as mosquito net distribution, indoor residual spraying and community-based disease surveillance.
Stronger partnerships with the private sector and innovative health financing mechanisms can also help to close funding gaps and strengthen national resilience.
Malaria is not merely a health issue; it is also an economic one. Outbreaks strain hospitals, disrupt productivity and deepen poverty in already vulnerable communities. Investing in prevention is far cheaper than repeatedly responding to crises.
Zimbabwe possesses the expertise, infrastructure and experience needed to sustain the progress made in malaria control. What is required is political will and firm financial commitment.
The recent resurgence should, therefore, be viewed as a wake-up call — and an opportunity to build a more resilient and self-reliant public health system.
A nation cannot outsource the protection of its citizens’ health.